BioprintingMedical AMTrends 2024

RegenHU and the role of iPSCs in bioprinting today

Part II of our exclusive series on exciting applications in bioprinting today

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

The medical AM segment is multifaceted, consisting of 3D printed medical devices, anatomical models, prosthetics and more. Within the industry, bioprinting has carved out a prominent position, gaining interest across the board for its huge potentials in drug development and screening, therapeutic treatments and regenerative medicine, to name but a few. While much of the excitement surrounding bioprinting is focused on the future, we want to look at what is happening now in the field that is exciting.

As part of our Medical AM Focus, we asked bioprinting leaders from across the sector what they consider to be the most exciting thing about bioprinting today. In the first of the series, we hear from Swiss bioprinting firm RegenHU.

RegenHU was founded in 2007 with the aim of developing bioprinting solutions to serve the scientific community. Today, the company offers a range of bioprinting products, including the BioFactory and 3DDiscovery Evolution printers, as well as many materials for soft and hard tissue engineering and drug discovery.

RegenHU bioprinting focus

The company has also worked with numerous partners across industry and academia, including L’Oréal, the National Institutes of Health, Trinity College Dublin, ETH Zurich and many, many more.

According to RegenHU, 3D bioprinting is progressing thanks to three key areas: the development of reliable and capable 3D bioprinter systems, the creation of new bioink formulations with tunable properties and the development of Induced Pluripotent Stem Cells (iPSC) derived cells, which can be programmed to become various types of cell.

“Already, protocols for bone and skin are being developed for clinical application, whilst more complex neuronal and liver tissues progress towards being acceptable tool systems for efficacy and toxicity testing in drug development, with the potential to improve clinical outcomes and patient safety,” the company says.

“The industrialization of human iPSC use, and development of robust differentiation methods to produce functional cell types, such as through bioink supported gene transfer, can enable multicellular organ development post printing. However, a better understanding of the interactions between these cell systems and bioinks is critical to understand the long term function of multicellular systems.”

One of the challenges that still shapes bioprinting research is vascularization—or the ability to print cells with a stable network of blood vessels, which provide the cells with nutrients.

RegenHU explains: “The difficulty producing and maintaining a stable network of blood vessels in larger and more cellular diverse 3D constructs is a limiting factor for the scale up of engineered tissues that is being addressed through new biomaterials that can drive vascularization. Maintaining the unique architecture of complex organs during and after printing is also challenging, however novel bioinks such as graphene-based materials show promise in successfully creating regenerative scaffolds for multiple tissue types including brain.”

“These key stepping stones move us closer to the future creation of whole organs for transplant and the development of therapeutic tissue replacement components, such as heart biopatches with conductive properties for arrhythmia treatment, that will revolutionize regenerative medicine and patient-specific treatment. At regenHU we are excited by these positive developments and are committed to helping our scientific collaborators as we maintain our major influence within this fast growing field.”

Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.